Guidelines to document H. pylori antimicrobial resistance in the North America: Difference between revisions

Revision as of 19:37, 1 December 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2], Sargun Singh Walia M.B.B.S.[3] ==2017 ACG Guidelines to document H. pylori antimicrobial resistance in the North America

==

Strong recommendation
1.Bismuth quadruple therapy consisting of a PPI, bismuth, tetracycline, and a nitroimidazole for 10–14 days is a recommended fi rst-line treatment option. Bismuth quadruple therapy is particularly attractive in patients with any previous macrolide exposure or who are allergic to penicillin
2.Concomitant therapy consisting of a PPI, clarithromycin, amoxicillin and a nitroimidazole for 10–14 days is a recommended fi rst-line treatment option

@@ Line 1: / Line 1: @@
 __NOTOC__
+{{CMG}}; {{AE}} {{MKK}}, {{SSW}}
+==2017 ACG Guidelines to document H. pylori antimicrobial resistance in the North America
+ ==
+{| class="wikitable"
+|-
+| colspan="1" style="text-align:center; background:LightGreen" |Strong recommendation
+|-
+| bgcolor="LightGreen" |1.Bismuth quadruple therapy consisting of a PPI, bismuth, tetracycline, and a nitroimidazole for 10–14 days is a recommended fi rst-line treatment option.
+Bismuth quadruple therapy is particularly attractive in patients with any previous macrolide exposure or who are allergic to penicillin
+|-
+| bgcolor="LightGreen" |2.Concomitant therapy consisting of a PPI, clarithromycin, amoxicillin and a nitroimidazole for 10–14 days is a recommended fi rst-line treatment option
+|-
+|}